News und Analysen

Several senior executives at Applied Therapeutics have recently sold company shares as part of "sell-to-cover" transactions to address tax liabilities related to restricted stock units. Interim CEO

In early March 2025, Merit Medical Systems' leadership team executed significant stock transactions totaling over $7 million. CEO Fred Lampropoulos sold 34,319 shares at prices between $103.75 and

Chimerix, a biotechnology company, experienced a remarkable surge in its stock price during Wednesday's pre-market trading, with shares climbing over 69% to reach $8.41. This exceptional performance

Cerus Corp (NASDAQ: CERS) recently saw several top executives sell company shares as part of a pre-established trading plan in early March 2025. CEO William Greenman sold 23,023 shares at an average

Several high-ranking executives at Penumbra Inc. have recently sold substantial amounts of company stock, with transactions beginning in early March 2025. Board member Arani Bose divested shares

Pfizer shares gained 0.9 percent on Wednesday in New York trading, closing at $25.98 after reaching an intraday high of $26.17. Investor interest remained strong with over one million shares

Abbott Laboratories is experiencing notable stock market activity as multiple senior executives recently divested portions of their holdings. Former Executive Vice President Andrea F. Wainer sold

Veeva Systems has introduced Commercial Pulse, a new data offering designed to enhance market segmentation and targeting for life sciences companies. This solution provides quarterly updates on

Merit Medical Systems Inc., a medical technology company with a market capitalization of $6.08 billion, has experienced significant stock transactions by its leadership team. The company's chief

Stereotaxis (NYSE: STXS), a pioneer in robotic technologies for minimally invasive endovascular procedures, has filed regulatory applications with the U.S. Food and Drug Administration for two

Vertex Pharmaceuticals Inc. has seen significant insider selling activity recently, with top executives divesting substantial shareholdings while the company's stock enjoys impressive performance

OraSure Technologies' stock is experiencing significant insider buying activity as multiple executives made substantial investments while shares trade near their 52-week low of €2.69. CEO Carrie

Novavax has significantly reduced its net loss in the fourth quarter of 2024 to $81.03 million ($0.51 per share), a substantial improvement from the $178.39 million ($1.44 per share) loss reported

Exelixis is experiencing significant insider selling activity while its stock trades near its 52-week high of €37.64. Three high-ranking executives recently reduced their holdings in substantial

Ocular Therapeutix, Inc. (NASDAQ: OCUL), the biotechnology firm with a market capitalization of $1.06 billion, recently reported several stock transactions by its leadership team. CEO Pravin Dugel

Pharmaceutical giant Eli Lilly and Company, now the world's most valuable pharma corporation with a market capitalization exceeding $855 billion, announced Wednesday it will invest an additional $27

Der Aktienkurs von Neurocrine Biosciences verzeichnet aktuell eine deutliche Abwärtsbewegung. Der Biotechnologie-Konzern notiert bei 116,00 USD und weist damit einen Rückgang von 2,61 Prozent zum

Morgan Stanley's optimistic outlook for Gilead Sciences' HIV prevention medication Lenacapavir has positioned the company for significant market advancement. The drug, anticipated to receive FDA

Eli Lilly continues to demonstrate remarkable market performance, posting an impressive 32 percent revenue growth over the past twelve months. The pharmaceutical giant's robust financial health is

Die ChromaDex-Aktie verzeichnete am 24. Februar 2025 einen beachtlichen Tagesgewinn von 2,95 Prozent und schloss bei 5,58 USD. Diese positive Entwicklung kommt zu einem strategisch wichtigen